Needham & Company reiterates a 'Buy' on Seattle Genetics (SGEN); B is for BLA, and Ved is for Very Exemplary Data - Pivotal Trial Results
Tweet Send to a Friend
Needham & Company reiterates a 'Buy' on Seattle Genetics (NASDAQ: SGEN), PT $18.
Needham analyst says, "The data from the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "The data from the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
